Hair-growth claims are a high-risk area for cosmetics businesses selling into the United States. The key question is not the product’s texture, packaging, or marketing category. It is the product’s intended use, which FDA can determine from claims on the label, website, advertising, and other promotional materials.
For a private-label brand, this means a shampoo, serum, oil, or scalp treatment may be marketed as a cosmetic only while its claims remain cosmetic. Statements that the product restores hair growth, regrows hair, treats hair loss, or prevents baldness can place it in drug territory. A compliant launch process therefore begins with claim classification before label design, manufacturing release, or marketplace listing.
Why hair-growth claims change the regulatory path
Under the Federal Food, Drug, and Cosmetic Act, a cosmetic is generally intended to cleanse, beautify, promote attractiveness, or alter appearance. A drug is generally intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body. FDA specifically uses restoring hair growth as an example of a drug claim.
The same formula can trigger different obligations when the intended use changes. A scalp-care product positioned for a cleaner-feeling scalp or hair that looks fuller is not evaluated in the same way as a product represented to regrow hair. Review every consumer-facing statement together: product name, front-panel language, directions, images, testimonials, paid ads, influencer briefs, product-detail pages, and social captions.
| Claim direction | Typical intended-use signal | Practical U.S. consequence |
|---|---|---|
| Cosmetic appearance or grooming | “Helps hair look fuller,” “improves shine,” or “leaves the scalp feeling refreshed” | Assess as a cosmetic claim, while ensuring the label and marketing remain truthful and not misleading. |
| Hair-growth or hair-loss treatment | “Regrows hair,” “restores hair growth,” “treats thinning,” or “prevents baldness” | Assess as a drug claim. A cosmetic-only compliance file is not enough. |
| Mixed claim set | A cosmetic benefit is paired with a therapeutic outcome in ads, testimonials, or product copy | FDA can consider the overall intended use; isolate and remove unsupported drug-facing language before launch. |
Classify the finished claim set—not just the label
Do not rely on a single “cosmetic” statement to neutralize a therapeutic message elsewhere. FDA explains that intended use may be established by claims, advertising, and consumer perception. This is particularly important for marketplace listings, where comparison charts, before-and-after images, customer reviews selected by the seller, and automated ad copy can materially change the impression of the product.
A useful internal rule is to route any proposed claim through a regulatory review when it includes an outcome such as growth, regrowth, restoration, prevention of hair loss, treatment of alopecia, follicle stimulation, or a measurable biological change. Terms such as “clinically proven” and “FDA approved” also require careful review; they should not be used as shortcuts for a substantiation assessment.
What a cosmetic brand may communicate
Cosmetic claims should describe appearance, cleansing, conditioning, fragrance, or the sensory experience without promising a therapeutic result. The claim must still be truthful, non-misleading, and supported by the evidence held by the responsible business. The right wording depends on the finished formula, the instructions for use, the target consumer, and the full marketing context.
Examples that may warrant a cosmetic-focused review include “helps hair look more voluminous,” “conditions dry-looking hair,” and “supports a healthy-looking scalp.” These examples are not pre-approved claim templates. A regulatory specialist should assess the complete wording and the impression created by the campaign before commercial use.
If the product is marketed for hair growth
Once a product is intended to restore or promote hair growth, the brand should treat the project as a drug-regulatory question rather than a cosmetic-labeling exercise. The applicable pathway, testing, labeling, manufacturing controls, and marketing limitations need to be evaluated for the specific active ingredient, dosage form, directions, and claims. Do not assume that a cosmetic contract manufacturer, cosmetic product information file, or cosmetic-style ingredient review satisfies drug requirements.
FDA warning letters also show why this distinction matters in practice. Promotional claims for hair growth can lead the agency to identify a product as an unapproved new drug or to question whether an OTC drug is being marketed in accordance with the applicable regulatory framework. Obtain qualified U.S. regulatory advice before taking a hair-growth product to market.
| Control point | Required launch action | Evidence to retain |
|---|---|---|
| Claim inventory | Collect every label, web, ad, marketplace, influencer, and sales claim before approval. | Version-controlled claim matrix with owner, rationale, and approval date. |
| Intended-use classification | Determine whether the finished claim set is cosmetic-only or raises drug requirements. | Regulatory assessment and documented decision record. |
| Substantiation | Match the level and type of support to each permitted claim before publication. | Study reports, test protocols, supplier documentation, and claim-support summary. |
| Label and listing control | Release only approved artwork, instructions, product pages, and ad variants. | Final approved copies and change-control history. |
Labeling, manufacturing, and marketplace controls
For cosmetic-only products, label review should address identity, net quantity, ingredient declaration, business information, warnings where needed, and the risk that a claim makes the labeling misleading. A product sold as a drug has a different regulatory analysis and should not be released under a cosmetic-only label strategy.
Contract manufacturers and brand owners should agree on a written approval workflow. The workflow should identify who may approve product claims, who owns substantiation records, how formula or fragrance changes are assessed, and how an online listing is locked after regulatory review. This protects the brand when copy is reused across distributors, retailers, affiliates, and regional websites.
For more U.S. product-classification context, see MOOYAM’s cosmetics compliance resources. The safest approach is to assess classification before the marketing team finalizes the promise, rather than trying to revise a drug-facing campaign after it is live.
Pre-launch checklist for a hair-care claim
- List all proposed consumer claims and visual implied claims.
- Confirm the intended use from the complete advertising and labeling context.
- Escalate any hair-growth, regrowth, hair-loss, or biological-function statement for U.S. drug-regulatory review.
- Verify that cosmetic-only statements are truthful, non-misleading, and supported.
- Approve the final label, product page, marketplace copy, and influencer brief as one controlled set.
- Re-review the claim file whenever the formula, directions, target market, or promotional message changes.
Key takeaways
“Hair growth” is not a cosmetic positioning claim in the United States. It is a signal to assess whether the product is a drug and whether a different regulatory pathway applies. Brands can reduce avoidable risk by controlling the entire claim ecosystem, retaining substantiation, and keeping cosmetic marketing focused on appearance and grooming benefits unless a qualified regulatory review supports a drug pathway.
Official sources
- FDA: Cosmetics Labeling Claims
- FDA: Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
- FDA: Cosmetics Labeling Guide
- FDA: Cosmetics Labeling Regulations
- FDA Warning Letter: Amwiner / RapheGenerics
Compliance disclaimer: This article provides general educational information, not legal advice. U.S. product classification depends on the finished product and its complete claims context. Obtain qualified regulatory and legal advice before marketing a product with hair-growth or hair-loss claims in the United States.